Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bintrafusp alfa - EMD Serono/GlaxoSmithKline/Merck KGaA

Drug Profile

Bintrafusp alfa - EMD Serono/GlaxoSmithKline/Merck KGaA

Alternative Names: Anti-PD-L1/TGFbetaRII-fusion-protein; GSK-4045154; M-7824; MSB-0011359C

Latest Information Update: 21 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer EMD Serono; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Biliary cancer
  • Phase II Non-small cell lung cancer; Prostate cancer; Recurrent respiratory papillomatosis; Solid tumours
  • Phase I/II Colorectal cancer; Pancreatic cancer; Small cell lung cancer
  • Phase I Breast cancer

Most Recent Events

  • 10 Jan 2020 MD Anderson cancer center and National Cancer Institute plans a phase I/II trial for Head and Neck cancer and Squamous cell cancer (Recurrent disease, Second-line therapy, Inoperable/Unresectable disease) (NCT04220775)
  • 10 Dec 2019 Efficacy results from a phase I trial in Solid tumours (from breast cancer expansion cohort) presented at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS-2019)
  • 20 Sep 2019 Phase-II/III clinical trials in Biliary cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA, Germany (IV) (NCT04066491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top